SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Pediatric Oncology Nursing
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1043454208321114v1
25/4/227    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gross-King, M.
Right arrow Articles by Couluris, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross-King, M.
Right arrow Articles by Couluris, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Neurocognitive Impairment in Children Treated for Cancer: How Do We Measure Cognitive Outcomes?

Margaret Gross-King, MS, RN

Moffitt CCOP Research Base at the University of South Florida, Tampa, Florida

Margaret Booth-Jones, PhD

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Marisa Couluris, DO

Moffitt CCOP Research Base at the University of South Florida, Tampa, Florida, Marisa.couluris{at}epi.usf.edu

As the number of childhood cancer survivors grows, more attention on the identification and management of late effects, such as neurocognitive decline, is needed. This study, investigating treatment with central nervous system (CNS) stimulants for cognitive changes related to pediatric cancer treatment, confirmed a common concern. How should neurocognitive decline be measured and followed up after cancer therapy? Multiple pediatric standardized cognitive tests are available, but there is no consensus on an efficient way to measure the most common areas of decline, specifically impaired concentration, memory, and mental processing speed. The authors' report recognized 12 pediatric patients at risk for cognitive dysfunction, of whom 3 tested positive for early neurocognitive deficits using 3 subscales of the Wechsler Intelligence Scale for Children—III (WISC-III), which measure working verbal memory (Digit Span), mental processing speed (Symbol Search), and psychomotor speed (Coding). To predict the expected level of performance on WISC-III subscales, the patients' IQ was estimated using the Wide Range Achievement Test—3 reading subtest. Patients were treated with long-acting CNS stimulants and followed up serially using the WISC-III subscales.

Key Words: Key words: intelligence quotient • Wide Range Achievement Test—3 • Wechsler Intelligence Scale for Children

This version was published on July 1, 2008

Journal of Pediatric Oncology Nursing, Vol. 25, No. 4, 227-232 (2008)
DOI: 10.1177/1043454208321114


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement